Ironwood Pharmaceuticals vs Phathom Pharmaceuticals
IRWD and PHAT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRWD and PHAT compare
Ironwood Pharmaceuticals is the larger company, worth 1.8 times as much as Phathom Pharmaceuticals ($801M against $447M).
Phathom Pharmaceuticals grew revenue faster over the last twelve months (86.8% versus 26.2% for Ironwood Pharmaceuticals).
Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −30.2% at Phathom Pharmaceuticals.
Ironwood Pharmaceuticals scores higher on the StockData Score (12 against 4 for Phathom Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRWD | PHAT |
|---|---|---|
| Size and price | ||
| Market cap | $801M | $447M |
| Share price | $4.85 | $5.50 |
| Change, 1 year | 43.9% | −62.2% |
| Change, 5 years | −56.5% | −72.2% |
| Beta (5Y) | 1.05 | 1.73 |
| Employees | 100 | 371 |
| StockData Score | ||
| Total score | 12 (better) | 4 |
| Valuation score | 6 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 6.3× | – |
| P/S | 2.1× | 1.6× (better) |
| EV/EBITDA | 3.1× | – |
| FCF yield | – | −4.7% |
| Fair value | $12.87 | – |
| Margin of safety | 62.3% | – |
| Growth | ||
| Revenue growth (TTM) | 26.2% | 86.8% (better) |
| Revenue growth, 5Y average | −5.3% | – |
| EPS growth, 5Y average | −25.6% | – |
| Profitability | ||
| Gross margin | – | 80.7% |
| Operating margin | 60.1% (better) | −9.3% |
| Net margin | 33.4% (better) | −30.2% |
| FCF margin | – | −7.7% |
| Financial health | ||
| Interest coverage | 7.2× (better) | −0.4× |
| Current ratio | 6.06 (better) | 1.76 |
| Altman Z-score | −1.91 (better) | −4.87 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.2% | 88.7% |
| Held by insiders | 16.0% | 12.2% |
| Insider net buying, 12 months | −$22.6M | $0 (better) |
| Short interest, % of float | 10.7% | 12.9% |
Go deeper
- IRWD stock overview
- IRWD income statement
- IRWD valuation and score
- PHAT stock overview
- PHAT income statement
- PHAT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.